0001654954-24-005886.txt : 20240509 0001654954-24-005886.hdr.sgml : 20240509 20240509161759 ACCESSION NUMBER: 0001654954-24-005886 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zomedica Corp. CENTRAL INDEX KEY: 0001684144 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38298 FILM NUMBER: 24930962 BUSINESS ADDRESS: STREET 1: 100 PHOENIX DRIVE STREET 2: SUITE 125 CITY: ANN ARBOR STATE: MI ZIP: 48108 BUSINESS PHONE: (734) 369-2555 MAIL ADDRESS: STREET 1: 100 PHOENIX DRIVE STREET 2: SUITE 125 CITY: ANN ARBOR STATE: MI ZIP: 48108 FORMER COMPANY: FORMER CONFORMED NAME: Zomedica Pharmaceuticals Corp. DATE OF NAME CHANGE: 20160908 8-K 1 zom_8k.htm FORM 8-K zom_8k.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 9, 2024

 

ZOMEDICA CORP.

(Exact name of registrant as specified in its charter)

 

Alberta, Canada

 

001-38298

 

N/A

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

100 Phoenix Drive, Suite 125, Ann Arbor, Michigan

 

48108

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (734) 369-2555

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Shares, without par value

ZOM

NYSE American

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On May 9, 2024, Zomedica Corp. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

 

The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this current report shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless we expressly set forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

 

Item 9.01 Exhibits.

 

(d) Exhibits

 

99.1

 

Press Release, dated May 9, 2024

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
-2-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ZOMEDICA CORP.

 

 

 

 

 

Date: May 9, 2024

By:

/s/ Peter Donato

 

 

 

Name: Peter Donato

 

 

 

Title: Executive President and Chief Financial Officer

 

 

 
-3-

 

 

Exhibit Index

 

99.1

 

Press Release, dated May 9, 2024

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
-4-

 

 EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm

 

EXHIBIT 99.1

 

Zomedica Announces First Quarter 2024 Financial Results: Revenue up 14% to $6.3 Million; 66% Gross Margin, and $91 Million in Liquidity

 

Performance Sets New Record for First Quarter Revenue

 

ANN ARBOR, MI / ACCESSWIRE / May 9, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the first quarter ended March 31, 2024.

 

2024 First Quarter Financial Highlights

 

Revenue for the first quarter of 2024 grew 14% to $6.3 million, compared to first quarter 2023 revenue, driven by 9% growth over the prior year in the Therapeutic Devices segment and 86% growth over the prior year in the Diagnostics segment.

 

 

·

 Consumable revenues grew to $4.0 million, up 7% over first quarter 2023 revenues of $3.8 million, and represent 64% of total sales.

 

·

 Capital revenues grew to $2.2 million, up 30% over first quarter 2023 revenues of $1.7 million.
 

Gross margin was 66% for the first quarter of 2024.

 

Total cash used during the quarter was $9.6 million. When adjusted for non-recurring one-time items, our non-GAAP operating burn was approximately $4.4 million, in line with first quarter expectations and previously provided annual guidance for 2024.

 

“During the first quarter, we built on the momentum generated during 2023,” commented Zomedica Chief Executive Officer, Larry Heaton. “As we continued to execute on our strategy to drive growth in 2024 and beyond, we delivered the strongest first quarter in company history.

 

“We are seeing the positive impact of our significantly expanded portfolio combined with the growth and optimization of our commercial organization. Supporting the accelerated adoption of our innovative technologies was a series of clinical data publications specifically highlighting the benefits of PulseVet across multiple indications as well as the diagnostic efficacy of TRUFORMA as compared to competitive platforms.”

 

“Looking ahead, we remain enthusiastic about the opportunity that exists for Zomedica. With our strategy in place to accelerate growth, maintain industry-leading margins, and capture efficiencies, we are very well positioned to scale the business to achieve profitability and grow revenue to $100 million and beyond,” concluded Mr. Heaton.

 

 
1

 

 

2024 First Quarter Results Review

 

Revenue for the three months ended March 31, 2024, was $6.3 million, compared to $5.5 million for the three months ended March 31, 2023, an increase of $0.8 million or approximately 14%. The increase was driven by growth in both operating segments: Therapeutic Devices and Diagnostics.

 

Cost of revenue was $2.1 million, compared to $1.6 million for the three months ended March 31, 2023, an increase of $0.5 million. Margins remained strong at 66%, in line with expectations. Adjusting for our Qorvo Biotechnologies LLC (“QBT”) acquisition and other one-time items brings our gross margin for the quarter to over 69%, in line with recent levels.

 

Operating expenses were $14.5 million, compared to $11.3 million for the three months ended March 31, 2023, an increase of $3.2 million or 28%. When adjusted for one-time, non-recurring charges, and expenses associated with ongoing QBT operations, total operating expenses grew just over 20% on a comparative basis. We continue to expect total operating expenses as a percentage of total revenue to decrease throughout the balance of the year.

 

Research and development expenses were $1.8 million, compared to $0.9 million for the three months ended March 31, 2023, an increase of $0.9 million or 100%. The increase was almost exclusively driven by the integration of our acquisition of QBT, and investments in acquiring CE marking, attesting to compliance with the European Commission’s safety and emissions standards, for our TRUFORMA, TRUVIEW and VetGuardian products, incorporating Artificial Intelligence (“AI”) into our TRUVIEW and VetGuardian products and developing new TRUFORMA assays for launch later this year.

 

Selling and marketing expense was $4.1 million, compared to $3.4 million for the three months ended March 31, 2023, an increase of $0.7 million or 20%. The increase was primarily due to our growing sales organization and higher trade show expenses associated with launching and marketing additional products at the two largest animal health trade shows which were held in the first quarter.

 

General and administrative expense was $8.6 million, compared to $7.0 million for the three months ended March 31, 2023, an increase of $1.6 million or 23%. The increase was primarily driven by professional fees for specialized accounting work and audit work associated with 2023 acquisitions; and additional fees related to programs associated with regaining compliance.

 

Net loss for the three months ended March 31, 2024, was $9.2 million, or $0.01 per share, compared to a net loss of $6.4 million, or $0.007 per share, for the three months ended March 31, 2023.

 

 
2

 

 

*Non-GAAP EBITDA loss (which includes adjustments for stock compensation) for the three months ended March 31, 2024, was $7.5 million compared to a loss of $4.1 million for the three months ended March 31, 2023. When adjusting for non-recurring items our **Adjusted Non-GAAP EBITDA loss was $6.2 million. When further adjusted for on-going QBT integration and associated direct labor costs the loss falls to approximately $5.3 million.

 

Liquidity and Outstanding Share Capital

 

Zomedica had cash, cash equivalents, and available-for-sale securities of $90.9 million as of March 31, 2024, compared to $100.5 million as of December 31, 2023. The decrease in cash was primarily driven by continued operations, additional operating expenses related to the QBT acquisition and other professional fees for specialized accounting work and audit work associated with 2023 acquisitions; and additional fees related to programs associated with regaining compliance.

 

As of March 31, 2024, Zomedica had 979,949,668 common shares issued and outstanding.

 

2024 Business Outlook and Financial Guidance

 

For the full year 2024, the Company continues to expect full year revenue in the range of $31 to $35 million, an increase of approximately 39% at the high end of the range, over full year 2023 revenue of $25.2 million.

 

Zomedica believes that growth in 2024 will be driven by its existing portfolio, including recently launched products, supported by investments the Company is making to continue to drive increased adoption and utilization of its products, as well as contributions from a number of new products that the Company expects to launch during 2024. Guidance for 2024 does not incorporate any positive benefits from acquisitions the Company may make during the year.

 

The Company expects that on a quarterly basis, revenues should increase sequentially from the first quarter, with the majority of revenue expected to be recorded during the back half of the year.

 

For complete financial results, please see Zomedica's filings on EDGAR and SEDAR or visit the Zomedica website at www.zomedica.com.

 

For percentage calculations please refer to the financial statements filed with the SEC on Thursday May 9, 2024 along with other public filings

 

 
3

 

 

Conference Call Details

 

Zomedica will host a conference call on Thursday, May 9, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its first quarter ended March 31, 2024. A question-and-answer session will follow management's prepared remarks.

 

Event: Zomedica Corp. Q1 2024 Financial Results Conference Call

 

Date: Thursday, May 9, 2024

 

Time: 4:30 p.m. Eastern Time

 

Live Call: +1-888-886-7786 (U.S. Toll-Free) or +1-416-764-8658 (International)

 

Webcast: LINK

 

For interested individuals unable to join the conference call, a dial-in replay of the call will be available until Thursday, May 23, 2024, at 11:59 PM ET and can be accessed by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) and entering replay pin number: 72335729.

 

About Zomedica

 

Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.

 

Follow Zomedica

 

 

·

 Email Alerts:http://investors.zomedica.com

 

·

 LinkedIn:https://www.linkedin.com/company/zomedica

 

·

 Facebook:https://m.facebook.com/zomedica

 

·

 X (formerly Twitter):https://twitter.com/zomedica

 

·

 Instagram:https://www.instagram.com/zomedica_inc

 

Cautionary Note Regarding Forward-Looking Statements

 

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

 

 
4

 

 

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.

 

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

 

 
5

 

 

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

 

Investor Relations Contact:

 

Zomedica Investor Relations

investors@zomedica.com

1-734-369-2555

 

SOURCE: Zomedica Corp.

 

Non-GAAP Measures

 

Non-GAAP EBITDA, Adjusted Non-GAAP EBITDA, and other measures presented on an adjusted basis are not recognized terms under U.S. GAAP and do not purport to be alternatives to the most comparable U.S. GAAP amounts. Since all companies do not use identical calculations, our definition and presentation of these measures may not be comparable to similarly titled measures reported by other companies. Management uses the identified non-GAAP measures to evaluate the operating performance of the Company and its business segments and to forecast future periods. Management believes these non-GAAP measures assist investors and other interested parties in evaluating Zomedica's on-going operations and provide important supplemental information to management and investors regarding financial and business trends relating to Zomedica's financial condition and results of operations. Investors should not consider these non-GAAP measures as alternatives to the related GAAP measures. Reconciliations of non-GAAP measures to their closest U.S. GAAP equivalent are presented below.

 

* Non-GAAP EBITDA is defined as net loss and comprehensive loss excluding amortization, depreciation, non-cash stock compensation, and taxes while reversing out the benefits derived from net interest income.

 

** Non-GAAP Adjusted EBITDA is defined as Non-GAAP EBITDA, as defined above, excluding non-recurring items; including but not limited to specialized accounting, tax, and audit services, costs associated with programs related to regaining and maintaining compliance with the NYSE, as well as the QBT integration and associated direct labor costs, and other one-time items.

 

 
6

 

 

 

 

For the 3 Months Ended

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As Presented

 

 

One-Time Items

 

 

Adjusted

 

 

As Presented

 

 

 

3/31/24

 

 

3/31/24

 

 

3/31/24

 

 

3/31/23

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

 $ 6,262

 

 

 $ —

 

 

 $ 6,262

 

 

 $ 5,482

 

Cost of revenue

 

 

 2,145

 

 

 

 (266 )

 

 

 1,879

 

 

 

 1,647

 

Gross profit

 

 

 4,117

 

 

 

 266

 

 

 

 4,383

 

 

 

 3,835

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

 8,625

 

 

 

 (1,605 )

 

 

 7,020

 

 

 

 7,013

 

Research and development

 

 

 1,771

 

 

 

 (322 )

 

 

 1,449

 

 

 

 918

 

Selling and marketing

 

 

 4,107

 

 

 

 —

 

 

 

 4,107

 

 

 

 3,416

 

Loss from operations

 

 

 (10,386 )

 

 

 2,193

 

 

 

 (8,193 )

 

 

 (7,512 )

Interest income

 

 

 1,093

 

 

 

 —

 

 

 

 1,093

 

 

 

 1,412

 

Interest expense

 

 

 —

 

 

 

 —

 

 

 

 —

 

 

 

 (50 )

Gain (loss) on disposal of assets

 

 

 12

 

 

 

 —

 

 

 

 12

 

 

 

 —

 

Other loss

 

 

 84

 

 

 

 —

 

 

 

 84

 

 

 

 (1 )

Impairment expense

 

 

 —

 

 

 

 —

 

 

 

 —

 

 

 

 —

 

Foreign exchange loss

 

 

 (129 )

 

 

 —

 

 

 

 (129 )

 

 

 (26 )

Loss before income taxes

 

 

 (9,326 )

 

 

 2,193

 

 

 

 (7,133 )

 

 

 (6,177 )

Income tax expense (benefit)

 

 

 (166 )

 

 

 —

 

 

 

 (166 )

 

 

 208

 

Net loss

 

 

 (9,160 )

 

 

 2,193

 

 

 

 (6,967 )

 

 

 (6,385 )

Unrealized gains, change in fair value of available-for-sale securities, net of tax

 

 

 (11 )

 

 

 —

 

 

 

 (11 )

 

 

 283

 

Change in foreign currency translation

 

 

 (52 )

 

 

 —

 

 

 

 (52 )

 

 

 3

 

Net loss and comprehensive loss

 

 $ (9,223 )

 

 $ 2,193

 

 

 $ (7,030 )

 

 $ (6,099 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjustments (Non-Cash)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization

 

 $ 1,597

 

 

 $ —

 

 

 $ 1,597

 

 

 $ 1,199

 

Depreciation

 

 

 334

 

 

 

 —

 

 

 

 334

 

 

 

 164

 

Stock Compensation

 

 

 1,101

 

 

 

 —

 

 

 

 1,101

 

 

 

 1,765

 

Subtotal

 

 $ (6,191 )

 

 $ 2,193

 

 

 $ (3,998 )

 

 $ (2,971 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest

 

 $ (1,093 )

 

 $ —

 

 

 $ (1,093 )

 

 $ (1,362 )

Taxes

 

 

 (166 )

 

 

 —

 

 

 

 (166 )

 

 

 208

 

Non-GAAP Adjusted EBITDA**

 

 $ (7,450 )

 

 $ 2,193

 

 

 $ (5,257 )

 

 $ (4,125 )

 

 
7

 

 EX-101.SCH 3 zom-20240509.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 zom-20240509_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity File Number Entity Incorporation State Country Code Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer EX-101.CAL 5 zom-20240509_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 6 zom-20240509_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 7 zom-20240509_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
May 09, 2024
Cover [Abstract]  
Entity Registrant Name ZOMEDICA CORP.
Entity Central Index Key 0001684144
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date May 09, 2024
Entity File Number 001-38298
Entity Incorporation State Country Code Z4
Entity Address Address Line 1 100 Phoenix Drive
Entity Address Address Line 2 Suite 125
Entity Address City Or Town Ann Arbor
Entity Address State Or Province MI
Entity Address Postal Zip Code 48108
City Area Code 734
Local Phone Number 369-2555
Security 12b Title Common Shares, without par value
Trading Symbol ZOM
Security Exchange Name NYSE
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://zom.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-60547-EntityTaxIdentificationNumber-Missing] Submission type 8-K should have a non-empty value for EntityTaxIdentificationNumber in the Required Context. zom_8k.htm zom-20240509.xsd zom-20240509_cal.xml zom-20240509_def.xml zom-20240509_lab.xml zom-20240509_pre.xml zom_8k.htm http://xbrl.sec.gov/dei/2023 true true JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "zom_8k.htm": { "nsprefix": "zom", "nsuri": "http://zom.com/20240509", "dts": { "schema": { "local": [ "zom-20240509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "zom-20240509_cal.xml" ] }, "definitionLink": { "local": [ "zom-20240509_def.xml" ] }, "labelLink": { "local": [ "zom-20240509_lab.xml" ] }, "presentationLink": { "local": [ "zom-20240509_pre.xml" ] }, "inline": { "local": [ "zom_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://zom.com/role/Cover", "longName": "000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-05-09to2024-05-09", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "zom_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-09to2024-05-09", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "zom_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 2", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://zom.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001654954-24-005886-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-24-005886-xbrl.zip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end XML 20 zom_8k_htm.xml IDEA: XBRL DOCUMENT 0001684144 2024-05-09 2024-05-09 iso4217:USD shares iso4217:USD shares 0001684144 false 8-K 2024-05-09 ZOMEDICA CORP. Z4 001-38298 100 Phoenix Drive Suite 125 Ann Arbor MI 48108 734 369-2555 false false false false false Common Shares, without par value ZOM NYSE